Pentoxifylline for Prevention of Contrast Induced Nephropathy in Chronic Kidney Diseased Patients in Intensive Care Unit
The Role of Pentoxifylline for Prevention of Contrast Induced Nephropathy in Chronic Kidney Diseased Patients in Intensive Care Unit
研究概览
详细说明
Contrast-induced acute kidney injury (AKI), which is also known as contrast-induced nephropathy (CIN), is defined as the development of AKI following contrast medium exposure, without an alternative aetiology.
Recently, the cyclic nucleotide phosphodiesterase (PDE) has emerged as a promising target for pharmacological intervention against chronic kidney disease (CKD) progression.
The nonselective PDE inhibitor pentoxifylline (PTX) is a methyl xanthine derivative. It's an old drug that exhibits prominent anti-inflammatory, anti-proliferative and anti-fibrotic activities both in vitro and in vivo. In addition to its classic indication for intermittent claudication. It has been used primarily to treat patients with peripheral arterial insufficiency.
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
El-Gharbia
-
Tanta、El-Gharbia、埃及、31527
- Tanta University
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Age from 18 to 65 years.
- Both sexes.
- The presence of chronic kidney disease (CKD) is defined according to the National Kidney Foundation-kidney disease Outcomes Quality Initiative guidelines with second or third stage.
- Urgent patients expected taking dye in stable cases of cardiac catheterization or pulmonary embolism with Geneva score (4-11).
Exclusion Criteria:
- Patients with CKD on renal replacement therapy.
- Respiratory failure.
- Cardiac failure.
- Liver failure.
- Methylxanthines hypersensitivity.
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Group I
Patients received hydration (100ml normal saline every hour (2400ml/day) with closed dynamic monitoring of the blood volume and 400 mg oral Pentoxifylline (PTX) three times per day [dose adjustment according to estimated glomerular filtration rate (eGFR)] from 24 hr before contrast to 48 hr after contrast procedure.
|
Patients received hydration (100ml normal saline every hour (2400ml/day) with closed dynamic monitoring of the blood volume and 400 mg oral Pentoxifylline (PTX) three times per day [dose adjustment according to estimated glomerular filtration rate (eGFR)] from 24 hr before contrast to 48 hr after contrast procedure.
|
|
有源比较器:Group II
Patient received hydration (100ml normal saline every hour (2400ml/day) with closed dynamic monitoring of the blood volume and placebo with same shape and color of Pentoxifylline (PTX) three times per day from 24 hr before contrast to 48 hr after contrast procedure.
|
Patient received hydration (100ml normal saline every hour (2400ml/day) with closed dynamic monitoring of the blood volume and placebo with same shape and color of Pentoxifylline (PTX) three times per day from 24 hr before contrast to 48 hr after contrast procedure.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of contrast induced nephropathy
大体时间:48 hours after contrast procedure.
|
Incidence of contrast induced nephropathy was recorded.
|
48 hours after contrast procedure.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Progress of glomerular filtration rate
大体时间:48 hours after contrast procedure.
|
Progress of glomerular filtration rate after use of pentoxifylline was recorded.
|
48 hours after contrast procedure.
|
|
Lenght of intensive care unit stay
大体时间:Till the end of procedure (Up to 4 hours)
|
Lenght of intensive care unit stay was recorded.
|
Till the end of procedure (Up to 4 hours)
|
|
Need of dialysis
大体时间:48 hours after contrast procedure.
|
Need of dialysis was recorded.
|
48 hours after contrast procedure.
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 36264MS591/5/24
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
IPD 共享时间框架
IPD 共享访问标准
IPD 共享支持信息类型
- 研究方案
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.